LIX1L蛋白通过调控胆汁酸代谢促进胆汁淤积性肝损伤
该研究探讨LIX1L在胆汁淤积性肝损伤中的作用,发现LIX1L在PSC/PBC患者及三种小鼠模型中表达升高,且BA通过Egr-1上调Lix1l;LIX1L缺失可减轻BDL和Mdr2-/-小鼠肝损伤,机制涉及miR-191-3p/LRH-1/Cyp7a1/Cyp8b1轴;AAV介导miR-191-3p递送可改善Mdr2-/-小鼠损伤。
要点
- LIX1L在胆汁淤积患者和小鼠模型中表达升高,且由BA/Egr-1轴驱动。
- LIX1L缺失通过上调miR-191-3p抑制LRH-1及Cyp7a1/Cyp8b1,减少BA合成,从而减轻肝损伤。
- AAV介导miR-191-3p肝脏递送可显著减轻Mdr2-/-小鼠胆汁淤积性肝损伤。
核心结论
- LIX1L缺失通过抑制胆汁酸合成减轻胆汁淤积性肝损伤,LIX1L是连接BA/Egr-1与miR-191-3p/LRH-1信号的关键节点,LIX1L和miR-191-3p可能成为胆汁酸相关肝胆疾病治疗靶点。
研究设计与样本
- 研究纳入PSC或PBC患者肝脏组织,并采用BDL、Mdr2-/-和CA喂养三种小鼠胆汁淤积模型。
- 使用Lix1l敲除小鼠、染色质免疫沉淀、miRNA微阵列及AAV介导的肝脏递送系统进行机制研究。
主要发现
- LIX1L在PSC和PBC患者肝脏、三种小鼠模型及BA刺激的原代小鼠肝细胞中表达增加。
- BA诱导的Lix1l上调依赖于转录激活因子Egr-1。
- LIX1L缺失减轻BDL和Mdr2-/-小鼠的胆汁淤积性肝损伤。
- miR-191-3p在WT-BDL小鼠肝脏中降低最显著,在Lix1l-/--BDL小鼠中恢复;miR-191-3p靶向下调LRH-1,抑制Cyp7a1和Cyp8b1表达。
- AAV介导肝脏递送miR-191-3p显著减轻Mdr2-/-小鼠胆汁淤积性肝损伤。
临床怎么用
- LIX1L和miR-191-3p可作为胆汁淤积性肝病潜在治疗靶点,尤其针对胆汁酸合成调控通路。
- AAV介导miR-191-3p肝脏递送在Mdr2-/-小鼠中显示治疗潜力,但尚未进入临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cholestatic liver diseases comprise a variety of disorders of bile formation and/or flow which generally result in progressive hepatobiliary injury. Regulation of bile acid (BA) synthesis and homeostasis is a promising strategy for the treatment of cholestatic liver disease. Limb expression 1-like protein (LIX1L) plays an important role in post-transcriptional gene regulation, yet its role in cholestatic liver injury remains unclear. METHODS: LIX1L expression was studied in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC), and 3 murine models of cholestasis (bile duct ligation [BDL], Mdr2 knockout [Mdr2-/-], and cholic acid [CA] feeding). Lix1l knockout mice were employed to investigate the function of LIX1L in cholestatic liver diseases. Chromatin immunoprecipitation assays were performed to determine whether Egr-1 bound to the Lix1l promoter. MiRNA expression profiling was analyzed by microarray. An adeno-associated virus (AAV)-mediated hepatic delivery system was used to identify the function of miR-191-3p in vivo. RESULTS: LIX1L expression was increased in the livers of patients with PSC and PBC, and in the 3 murine models, as well as in BA-stimulated primary mouse hepatocytes. BA-induced Lix1l upregulation was dependent on Egr-1, which served as a transcriptional activator. LIX1L deficiency attenuated cholestatic liver injury in BDL and Mdr2-/- mice. MiR-191-3p was the most reduced miRNA in livers of WT-BDL mice, while it was restored in Lix1l-/--BDL mice. MiR-191-3p targets and downregulates Lrh-1, thereby inhibiting Cyp7a1 and Cyp8b1 expression. AAV-mediated hepatic delivery of miR-191-3p significantly attenuated cholestatic liver injury in Mdr2-/- mice. CONCLUSIONS: LIX1L deficiency alleviates cholestatic liver injury by inhibiting BA synthesis. LIX1L functions as a nexus linking BA/Egr-1 and miR-191-3p/LRH-1 signaling. LIX1L and miR-191-3p may be promising targets for the treatment of BA-associated hepatobiliary diseases. LAY SUMMARY: Bile acid homeostasis can be impaired in cholestatic liver diseases. Our study identified a novel mechanism of positive feedback regulation in cholestasis. LIX1L and miR-191-3p represent potential therapeutic targets for cholestatic liver diseases.
引用
- Li J, Zhu X, Zhang M, et al. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism. J Hepatol. 2021. PMID: 33746084. doi:10.1016/j.jhep.2021.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。